These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20564143)

  • 1. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun SY; Strychor S; Tighiouart M; Egorin MJ; Fu H; Khuri FR
    Cancer; 2010 Aug; 116(16):3903-9. PubMed ID: 20564143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
    Moulder S; Gladish G; Ensor J; Gonzalez-Angulo AM; Cristofanilli M; Murray JL; Booser D; Giordano SH; Brewster A; Moore J; Rivera E; Hortobagyi GN; Tran HT
    Cancer; 2012 May; 118(9):2378-84. PubMed ID: 22006179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
    Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z; Klass CM; Shin DM; Fu H; Sun SY; Govindan R; Khuri FR
    J Thorac Oncol; 2013 Mar; 8(3):369-72. PubMed ID: 23407561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
    Fury MG; Sherman E; Ho AL; Xiao H; Tsai F; Nwankwo O; Sima C; Heguy A; Katabi N; Haque S; Pfister DG
    Cancer; 2013 May; 119(10):1823-31. PubMed ID: 23408298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
    Argiris A; Kut V; Luong L; Avram MJ
    Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
    Kaira K; Tsuchiya S; Sunaga N; Yanagitani N; Watanabe S; Imai H; Hisada T; Ishizuka T; Saito R; Mori M
    Am J Clin Oncol; 2007 Feb; 30(1):51-6. PubMed ID: 17278895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
    Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
    J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of second-line chemotherapy with docetaxel and carboplatin in advanced non-small-cell lung cancer.
    Oka M; Fukuda M; Nagashima S; Fukuda M; Kinoshita A; Soda H; Doi S; Narasaki F; Suenaga M; Takatani H; Nakamura Y; Kawabata S; Tsurutani J; Kanda T; Kohno S
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):446-50. PubMed ID: 11800024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
    Schneider BJ; Kalemkerian GP; Bradley D; Smith DC; Egorin MJ; Daignault S; Dunn R; Hussain M
    Invest New Drugs; 2012 Feb; 30(1):249-57. PubMed ID: 20686817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
    Gelmon KA; Stewart D; Chi KN; Chia S; Cripps C; Huan S; Janke S; Ayers D; Fry D; Shabbits JA; Walsh W; McIntosh L; Seymour LK
    Ann Oncol; 2004 Jul; 15(7):1115-22. PubMed ID: 15205207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
    Milton DT; Riely GJ; Azzoli CG; Gomez JE; Heelan RT; Kris MG; Krug LM; Pao W; Pizzo B; Rizvi NA; Miller VA
    Cancer; 2007 Aug; 110(3):599-605. PubMed ID: 17577220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
    Vansteenkiste J; Solomon B; Boyer M; Wolf J; Miller N; Di Scala L; Pylvaenaeinen I; Petrovic K; Dimitrijevic S; Anrys B; Laack E
    J Thorac Oncol; 2011 Dec; 6(12):2120-9. PubMed ID: 21900840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
    Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
    Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
    Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.